310 related articles for article (PubMed ID: 15198341)
1. CpG DNA, liposome and refined antigen oral cholera vaccine.
Leelawongtawon R; Somroop S; Chaisri U; Tongtawe P; Chongsa-nguan M; Kalambaheti T; Tapchaisri P; Pichyangkul S; Sakolvaree Y; Kurazono H; Hayashi H; Chaicumpa W
Asian Pac J Allergy Immunol; 2003 Dec; 21(4):231-9. PubMed ID: 15198341
[TBL] [Abstract][Full Text] [Related]
2. Traffic of antibody-secreting cells after immunization with a liposome-associated, CpG-ODN-adjuvanted oral cholera vaccine.
Somroop S; Tongtawe P; Chaisri U; Tapchaisri P; Chongsa-nguan M; Srimanote P; Chaicumpa W
Asian Pac J Allergy Immunol; 2006 Dec; 24(4):229-38. PubMed ID: 17348246
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and protective role of three formulations of oral cholera vaccine.
Kalambaheti T; Chaisri U; Srimanote P; Pongponratn E; Chaicumpa W
Vaccine; 1998; 16(2-3):201-7. PubMed ID: 9607031
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of mucosal immune response following oral administration of enterotoxigenic Escherichia coli fimbriae (CFA/I) entrapped in liposomes in conjunction with inactivated whole-cell Vibrio cholerae vaccine.
Dima VF; Ionescu MD; Palade R; Balotescu C; Becheanu G; Dima SV
Roum Arch Microbiol Immunol; 2001; 60(1):27-54. PubMed ID: 11850896
[TBL] [Abstract][Full Text] [Related]
5. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
Liao J; Gibson JA; Pickering BS; Watnick PI
mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
[TBL] [Abstract][Full Text] [Related]
6. Oral vaccine against cholera prepared from Vibrio cholerae antigen(s).
Chaicumpa W; Chaisri U; Tapchaisri P; Chongsa-Nguan M; Pongponratn E
Southeast Asian J Trop Med Public Health; 1987 Jun; 18(2):142-8. PubMed ID: 3313733
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers.
Chaicumpa W; Chongsa-nguan M; Kalambaheti T; Wilairatana P; Srimanote P; Makakunkijcharoen Y; Looareesuwan S; Sakolvaree Y
Vaccine; 1998 Apr; 16(7):678-84. PubMed ID: 9562686
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of liposome-associated oral cholera vaccine prepared from combined Vibrio cholerae antigens.
Chaicumpa W; Parairo JR; New RC; Pongponratn E; Ruangkunaporn Y; Tapchaisri P; Chongsa-nguan M
Asian Pac J Allergy Immunol; 1990 Dec; 8(2):87-94. PubMed ID: 2091663
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of two formulations of oral cholera vaccines in Thai volunteers.
Chongsa-nguan M; Chaicumpa W; Ruangkunaporn Y; Looareesuwan S
Vaccine; 1991 Jan; 9(1):53-9. PubMed ID: 2008802
[TBL] [Abstract][Full Text] [Related]
10. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
[TBL] [Abstract][Full Text] [Related]
11. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
12. A one dose experimental cholera vaccine.
Muse M; Grandjean C; Wade TK; Wade WF
FEMS Immunol Med Microbiol; 2012 Oct; 66(1):98-115. PubMed ID: 22612159
[TBL] [Abstract][Full Text] [Related]
13. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
McCluskie MJ; Weeratna RD; Davis HL
Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
[TBL] [Abstract][Full Text] [Related]
15. The roles of mesoporous silica and carbon nanoparticles in antigen stability and intensity of immune response against recombinant subunit B of cholera toxin in a rabbit animal model.
Karimi Bavandpour A; Bakhshi B; Najar-Peerayeh S
Int J Pharm; 2020 Jan; 573():118868. PubMed ID: 31765785
[TBL] [Abstract][Full Text] [Related]
16. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
18. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria.
Viret JF; Favre D; Wegmüller B; Herzog C; Que JU; Cryz SJ; Lang AB
Infect Immun; 1999 Jul; 67(7):3680-5. PubMed ID: 10377160
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model.
Roy N; Barman S; Ghosh A; Pal A; Chakraborty K; Das SS; Saha DR; Yamasaki S; Koley H
FEMS Immunol Med Microbiol; 2010 Oct; 60(1):18-27. PubMed ID: 20528929
[TBL] [Abstract][Full Text] [Related]
20. Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.
Pierce NF; Cray WC; Sacci JB
Infect Immun; 1982 Aug; 37(2):687-94. PubMed ID: 6889574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
